| ObjectiveRetrospective analysis the therapeutic effects on non-blastic phase CML patients with the treatment of imatinib mesylate therapy.MethodsAll the patients were in the Hematology Department, the first affiliated hospital of Guangxi Medical University. The clinic information was analyzed by the retrospective method, including CHR, CCR, CMR rates, in patients with CML from September,2005to December,2011in our hospital. The overall survival rate and the progression free survival rate were estimated at6year.Results1.102patients, consisted of70males and32females,86patients in CP,16patients in AP. The CHR rate in CP at18months was98%. The median time of CHR in AP was7(3-28) months.2.41patients in CP initiated IM therapy more than24months.24of41(58.5%) patients achieved CCR at12months. At18months,33of41patients(80.5%) achieved CCR. The CMR rate at18months was51.2% 3. The estimated overall survival rate in CP at6year was96.5%, the estimated progression free survival rate at6year was93.0%.4. The patients in AP had low CCR rate.5. The hematological toxicities of IM therapy were tolerable. The most common nonhematological toxicities in our investigation was edema.Conclusion1. High rate of CCR and progression free survival rate and overall survival rate were achieved in CML patients of chronic phase treated with imatinib. The outcome is optimal.2. The rate of CCR was increased, if IM was initiated as early as possible. IM should be recommended as primary treatment for CML patients in CP.3. IM treatment should be initiated in CP as early as possible so as to get favorable response in patients. With dose increasement of IM, or other effective drugs, it can reduce the progression to AP in clinic practice.4. IM as a primary treatment for CML-CP could significantly improve the survival time and prolong the progression free survival time, and gave the patients great benefit.5. Early IM therapy could be effective and safe, the adverse effect of IM therapy were tolerable. |
PDF Full Text Request